ISRIB for Health & Longevity

Evidence Review created on 09/04/2026 using AI4L / Opus 5

Also known as: Integrated Stress Response Inhibitor, trans-ISRIB, ISRIB (trans-isomer)

Motivation

ISRIB (integrated stress response inhibitor) is an experimental compound that lifts a built-in brake on protein production inside cells. When a cell is damaged, starved, infected, or simply old, it pulls this brake and sharply slows the making of new proteins. That is useful in a short emergency, but nerve cells need fresh proteins to lay down memories, so a brake left engaged for years leaves a brain less able to learn.

The compound was found by chance during a search for something else, and attention grew when mice given a few doses learned faster and old mice regained lost memory. It has since been given to animals modelling head injury, dementia, and inherited disorders of the brain’s insulating layer. No person has ever received it in a registered clinical trial, yet it is sold as a research chemical and a few people with a fatal nerve disease have taken it themselves.

This review examines what is established about ISRIB: how it acts on cells, what the animal and laboratory evidence does and does not show, how related compounds have performed in people, which measures the literature ties to tracking its effects, and who paid for the work.

Benefits - Risks - Protocol - Conclusion

Grokipedia

ISRIB

A dedicated encyclopedia entry covering the compound’s chemistry, discovery, binding site on eIF2B, animal results across neurological models, and its unresolved bioavailability problem.

Examine

No Examine article exists for ISRIB. Examine covers dietary supplements and nutrition. ISRIB is neither a supplement nor a prescription medicine but an unapproved investigational compound, so it falls outside that scope.

ConsumerLab

No ConsumerLab article exists for ISRIB. ConsumerLab tests marketed supplements and foods. ISRIB is neither a supplement nor a prescription medicine but an unapproved research chemical, so it falls outside that programme.

Systematic Reviews

A single systematic review covers ISRIB’s class alongside agents acting on PERK (one of four sensor enzymes that halt protein production under stress) and agents that prolong the integrated stress response (ISR), the network all of them target.

Directional Modulation of the Integrated Stress Response in Neurodegeneration: A Systematic Review of eIF2B Activators, PERK-Pathway Agents, and ISR Prolongers - Stoian et al., 2026

Twelve mammalian in vivo studies; ISRIB helped in three of four, with one null Alzheimer’s result, and was tolerated better than PERK inhibitors.

ISRIB carries a genuine trade-off — releasing a brake that also protects cells — but only the benefit side is represented in the systematic review literature. No systematic review or meta-analysis of ISRIB’s harms, of chronic integrated stress response suppression, or of the forgone protection from blocking a survival pathway has been published; that side of the trade-off is unrepresented.

Mechanism of Action

Cells meet viral infection, amino-acid shortage, misfolded proteins, or mitochondrial damage by switching on one of four kinases (enzymes that attach phosphate groups): PERK, PKR, GCN2 and HRI. All four converge on one target — they phosphorylate eIF2α, part of the machine that loads the first amino acid onto the ribosome. Phosphorylated eIF2α then traps and inhibits eIF2B (which recharges eIF2 for another round), throttling overall protein synthesis while selectively increasing production of ATF4 (a transcription factor that turns on stress and cell-death genes). This network is the integrated stress response (ISR).

ISRIB binds a pocket at the symmetry axis of eIF2B and acts as a molecular staple, holding it in its active shape so nucleotide exchange continues despite phosphorylated eIF2α (Zyryanova et al., 2021). It leaves the four kinases untouched, so it lowers the output of the alarm rather than silencing it.

Two mechanistic readings compete. One holds that a low-grade ISR running for years in aged or injured tissue is maladaptive, so relieving it restores function. The other holds the ISR is protective, and blunting it strips out a survival programme — supported by accelerated motor-neuron loss in treated mice and impaired protein clearance in treated cells.

Reported properties: half-maximal effect near 5 nM; selective for eIF2B, with no kinase activity; plasma half-life roughly eight hours in mice, with good brain entry but poor water solubility limiting absorption; human metabolic route and enzymes (for example CYP3A4, a liver drug-metabolising enzyme) unpublished.

Historical Context & Evolution

ISRIB was not designed as a memory drug. It came out of a cell-based screen at the University of California, San Francisco for molecules that blunt PERK signalling, intended as a chemical probe of the unfolded protein response (the cell’s reaction to misfolded proteins). The cognitive effect was incidental: treated mice and rats learned water-maze and fear tasks faster, which led the authors to conclude that memory consolidation is normally limited by the ISR and that ISRIB releases that limit (Sidrauski et al., 2013).

Interest for health optimisation followed from three findings. Partial restoration of protein synthesis protected mice infected with prions (infectious misfolded proteins) from neurodegeneration without the pancreatic damage that PERK inhibitors cause (Halliday et al., 2015). Cognitive deficits reversed weeks after head injury and stayed reversed after dosing stopped (Chou et al., 2017). Old mice regained spatial and working memory after a brief course (Krukowski et al., 2020).

The record is not uniform. ISRIB did not rescue learning in one amyloid-overexpressing mouse line (Johnson & Kang, 2016), and cells become insensitive to it once phosphorylated eIF2α passes a threshold (Rabouw et al., 2019). Rather than resolve these, industry moved on: Calico Life Sciences and AbbVie — both with a direct commercial stake in this class — advanced soluble analogues, since ISRIB’s own solubility limited absorption (Frost et al., 2026). Whether the parent compound would have behaved differently in people is untested and now unlikely to be tested.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the entire ISRIB efficacy literature consists of rodent behaviour, rodent histology, and cell-culture assays, with no human clinical endpoint or validated clinical surrogate ever measured because ISRIB has never entered a registered trial.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial and no observational human data set on ISRIB exposure and any outcome.

Low 🟩

Speculative 🟨

Memory and Learning Performance ⚠️ Conflicted

Restoring hippocampal protein synthesis reversed memory deficits in aged and brain-injured rodents, but not in one amyloid model. All evidence is animal. Net: the effect looks real but strongly model-dependent.

Neuronal and Myelin Preservation

Treatment increased survival of myelin-making cells (those that insulate nerve fibres) and doubled lifespan in a mouse model of inherited brain-insulation disease. It also prevented prion neurodegeneration. Basis is animal models only.

Locomotor Recovery After Spinal Cord Injury

Treatment improved locomotor function after spinal cord injury in mice by curbing nerve-cell death and inflammation, replicating an earlier rodent result. Basis is animal models only.

Cerebral Glucose Uptake

In Alzheimer’s-model mice, treatment restored brain glucose transporter levels and improved glucose uptake alongside cognition. Basis is mouse imaging and tissue work; no human brain-metabolism data exist.

Hearing Preservation During Platinum Chemotherapy

Co-treatment reduced cisplatin-induced hearing loss in mice by damping the same stress pathway in inner-ear cells. Evidence is a single rodent study with no human replication.

Ovarian Follicle Activation

Treatment activated dormant ovarian follicles in mice and in cultured human ovarian tissue, acting through mTOR (a master growth-signalling pathway). Human tissue was studied outside the body only.

Reduced Cellular Senescence in Injured Lung

Treatment blocked senescence of lung lining cells (cells that stop dividing but linger) and reduced silica-induced lung scarring in mice. Senescence is an ageing hallmark. Basis is one rodent model.

Depression-Like Behaviour Under Chronic Stress

Two weeks of treatment restored sucrose preference and reduced immobility in restraint-stressed mice by damping overactive stress-hormone signalling, with weaker effects in females. Basis is one rodent model.

Protection of the Intestinal Barrier Under Chronic Stress

Treatment reduced stress-driven injury and inflammation of the gut lining in restrained mice by damping the same pathway where it drives barrier breakdown. Basis is one rodent model with no human data.

Benefit-Modifying Factors

Baseline stress-pathway tone: ISRIB only works below a threshold of phosphorylated eIF2α; once the signal is strong, cells become insensitive. Chronic low-grade activation is the responsive state; acute severe stress is not.
Genetic variants in the target itself: Mutations in the EIF2B1–EIF2B5 genes, which encode the enzyme ISRIB stabilises, destabilise it and define the population where the class shows the clearest effect. No pharmacogenetic data exist for ISRIB in people.
Sex: In repetitive head-trauma mice, the behavioural change ISRIB reversed appeared in males but not females. Several other efficacy studies used male animals only, so female response is under-characterised.
Pre-existing health conditions: Benefit tracked with whether the pathology was actually driven by this pathway. Head injury, ageing and brain-insulation disease models responded; an amyloid-overexpressing model did not, despite comparable dosing.
Age: Older animals showed the largest gains because baseline pathway activity rises with age, leaving more to relieve. In young healthy animals the memory effect was smaller and less consistent.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: there are no documented human adverse events for ISRIB, because no registered trial has ever administered it and no case series has been published.

Medium 🟥 🟥

No risk reaches Medium: there is no single human trial and no observational human safety data set for ISRIB.

Low 🟥

Speculative 🟨

Impaired Clearance of Damaged Proteins

Treatment blocked protein disposal by the proteasome (the cell’s shredder for damaged proteins) during stress in cultured cells, letting defective products accumulate. Basis is cell culture only; no whole-organism consequence has been measured.

Accelerated Motor Neuron Loss

Two eIF2B activators of ISRIB’s class brought forward disease onset and shortened survival in a motor-neuron-disease mouse model. Basis is analogue compounds in one animal model, not ISRIB itself.

Altered Response to Infection ⚠️ Conflicted

Treatment restored viral protein production early in picornavirus infection, yet hastened tuberculosis clearance in mice. Basis is cell and rodent work. Net: the direction depends entirely on the pathogen.

Altered Tumour Behaviour ⚠️ Conflicted

The stress response protects tumour cells, yet ISRIB killed leukaemia cells alongside imatinib and macrolides that activate it promoted tumour growth. Basis is cells and mice. Net: unresolved and cancer-type specific.

Accelerated Depletion of Ovarian Reserve

The same follicle activation offered as a fertility benefit recruits dormant follicles from a pool that is never replenished. Basis is mechanism plus rodent and cultured human tissue; long-term reserve was not measured.

Cardiovascular Effects Seen with Close Analogues

The truncated analogue 2BAct was withdrawn from development because of cardiovascular effects in higher species. Basis is non-rodent animal toxicology on a related molecule, not ISRIB.

Harm from Long-Term Suppression of a Protective Pathway

A safety commentary argues that off-target activity and chronic suppression of a survival programme remain wholly uncharacterised. Basis is mechanistic reasoning; no chronic-toxicity study of ISRIB has been published.

Risk-Modifying Factors

Genetic background: Carriers of mutations in SOD1 (a gene for an enzyme that neutralises reactive oxygen) causing inherited motor neuron disease are the clearest concern, since eIF2B activators worsened outcomes in SOD1-mutant mice.
Baseline stress-pathway tone: Low baseline pathway activity means the protective programme is being removed with little to gain. High activity blunts the drug but also signals an acute stress state in which the protective programme is most load-bearing.
Sex: Females carry the reproductive risk, since follicle activation depletes a non-renewable pool. No equivalent male reproductive toxicology has been published, so male risk is unknown rather than absent.
Pre-existing health conditions: Active malignancy, active infection, and any condition already burdening protein clearance amplify the mechanistic risks. Liver or kidney impairment matters because clearance routes in humans are unpublished.
Age: Older adults accumulate more damaged protein, so impaired clearance costs more. They are also likelier to take medicines that prolong the QT interval (the heart’s electrical reset), compounding the analogue cardiovascular signal.

Key Interactions & Contraindications

No human interaction study of ISRIB exists. Everything below is mechanistic prediction or animal data.

Proteasome inhibitors (bortezomib, carfilzomib, ixazomib): Absolute contraindication. ISRIB independently impairs clearance of damaged protein, so combining them compounds that burden. No mitigation is known; separation in time does not help because the effects are on the same process.
Platinum chemotherapy (cisplatin, carboplatin, oxaliplatin): Caution. ISRIB reduced cisplatin hearing damage in mice without blunting its killing of head-and-neck cancer cells, but other tumour types are untested. Consequence would be reduced anti-tumour effect. Mitigation: oncology supervision of any concurrent use.
Tyrosine kinase inhibitors (cancer drugs blocking growth-signal enzymes; imatinib, ponatinib, dasatinib): Monitor. ISRIB was additive against leukaemia cells with imatinib, while the stress response itself worsens ponatinib heart toxicity, so the direction differs by agent. Mitigation: cardiac monitoring if combined with ponatinib.
Macrolide antibiotics (azithromycin, clarithromycin, erythromycin): Caution. These activate the same pathway ISRIB blocks, so each blunts the other. Consequence is unpredictable net effect. Mitigation: separation of courses by at least the duration of antibiotic treatment.
QT-prolonging medicines (amiodarone, sotalol, citalopram, ondansetron): Caution. A close structural analogue was dropped for cardiovascular effects in large animals. Consequence is added risk of irregular heartbeat. Mitigation: electrocardiogram before and during, with avoidance above a corrected QT of 450 ms.
Over-the-counter analgesics (high-dose paracetamol, ibuprofen, naproxen): Monitor. These impose cellular stress that engages the same pathway, so effects oppose. Consequence is reduced ISRIB effect plus unquantified additive liver load. Mitigation: a paracetamol ceiling below 2 g daily.
Chemical chaperone supplements (TUDCA, taurine-conjugated bile acids, 4-phenylbutyrate): Caution, additive. These reduce endoplasmic reticulum stress (strain in the cell’s protein-folding compartment) upstream while ISRIB acts downstream on the same axis. Consequence is deeper loss of protection. Mitigation: no concurrent use of both.
Translation-promoting supplements (leucine, creatine, essential amino acid blends): Caution, additive. Both push protein synthesis upward, ISRIB by releasing the brake and these by driving mTOR. Consequence is amplified growth signalling of unknown safety. Mitigation: no stacking during an ISRIB course.
Stress-pathway-activating botanicals (high-dose curcumin, resveratrol, green-tea catechins, berberine): Monitor. At supplemental doses these induce cellular stress signalling that ISRIB opposes, blunting both. Consequence is wasted exposure to both. Mitigation: separation by several half-lives, roughly a day.
Rapamycin and other mTOR inhibitors: Caution. Rapamycin suppresses protein synthesis as a deliberate longevity strategy; ISRIB restores it. Consequence is direct opposition, undermining the rationale for either. Mitigation: no concurrent use.
Extended fasting, protein restriction and ketogenic diets: Monitor. Amino-acid scarcity activates GCN2, one of the four upstream kinases, so ISRIB opposes a signal these regimens are intended to produce. Mitigation: dosing outside fasting windows.

Populations who should avoid ISRIB:

Anyone with active or recent malignancy, or within five years of treatment for a solid tumour
Anyone with amyotrophic lateral sclerosis (a fatal motor neuron disease) or a known SOD1 mutation
Anyone with an active viral or bacterial infection until it has fully resolved
Women who are pregnant, breastfeeding, attempting conception, or who wish to preserve ovarian reserve
Anyone with congenital long QT syndrome, or a corrected QT interval above 470 ms in men or 480 ms in women
Anyone with moderate or severe liver impairment (Child-Pugh Class B or C) or an estimated glomerular filtration rate (a measure of kidney filtering) below 45 mL/min/1.73 m²
Anyone under 18 years of age

Risk Mitigation Strategies

Identity and isomer verification: A batch certificate of analysis showing the trans-isomer at ≥98% purity by high-performance liquid chromatography establishes identity, since the cis-isomer is inactive. This mitigates dosing a mislabelled or inactive material.
Cardiac baseline and follow-up: A 12-lead electrocardiogram before starting and again at two weeks, with a stopping threshold above a corrected QT interval of 450 ms, brackets exposure. This mitigates the cardiovascular signal seen with the close analogue 2BAct.
Malignancy and infection screening first: Documented absence of active cancer, recent tumour treatment and current infection precedes any exposure. This mitigates the unresolved tumour-behaviour risk and the blunting of antiviral defences.
Keep exposure short and intermittent: Published rodent efficacy used two to three doses, not continuous dosing, and effects persisted for weeks. Short courses mitigate the uncharacterised harm of chronically suppressing a protective survival pathway.
Ovarian reserve preservation: Anti-Müllerian hormone (a marker of egg reserve) at baseline and six months is the available tracking option for women of reproductive age. This mitigates silent depletion of the dormant follicle pool that follicle activation recruits.
Removal of proteasome-loading agents: Withdrawal of proteasome inhibitors and other sources of damaged protein during a course removes the additive load. This mitigates the additive impairment of damaged-protein clearance seen in treated cells.
Liver and pancreatic enzyme monitoring: Alanine and aspartate aminotransferase (liver enzymes) and lipase (a pancreatic enzyme) at baseline, week four and quarterly form the safety panel. This mitigates unrecognised organ injury from a compound whose human clearance is unpublished.

Therapeutic Protocol

No validated human protocol exists. ISRIB is not approved anywhere, has no prescribing information, and no clinic has published a dosing standard. What follows is the only protocol information in the literature.

Preclinical reference regimen: Rodent efficacy studies used 0.1–2.5 mg/kg by injection into the abdominal cavity, typically two or three doses, with benefits persisting for weeks. No validated conversion of that dose to humans has been published.
Competing approach — activate rather than inhibit: Sephin1 and IFB-088 prolong the same response instead of blunting it, and improved outcomes in the same systematic review. Neither direction has been shown superior in people.
Competing approach — soluble successors: Calico and AbbVie abandoned ISRIB for fosigotifator, an oral form engineered to dissolve better, taken daily. Both organisations hold a commercial stake in that compound rather than in ISRIB.
Originating groups: The Walter laboratory at the University of California, San Francisco developed ISRIB; the Rosi laboratory there produced the head-injury and ageing work. Neither published a human protocol.
Best time of day: No human timing data exist. Rodent dosing occurred during the animals’ light phase, which corresponds to their rest period, so the schedule does not translate directly to human daytime dosing.
Half-life: Roughly eight hours in mouse plasma, with good brain entry. Human half-life has never been measured. The eight-hour figure is the only pharmacokinetic anchor available and comes from a single species.
Single versus split dosing: Untested in humans. Rodent work used single injections rather than divided doses, and poor water solubility makes oral absorption erratic, which argues against extrapolating any split-dose schedule.
Genetic influences on dose: No pharmacogenetic data exist. Variants in EIF2B1–EIF2B5, which encode the target enzyme, are the only genotypes with a mechanistic reason to alter response, and that reasoning is untested in people.
Sex differences in response: Efficacy in the head-trauma model appeared in male mice only, and several other studies used males exclusively. No dose adjustment by sex can be derived from the available work.
Age-related considerations: Older animals showed larger effects because baseline pathway activity rises with age. In humans over 65, unpublished clearance routes and higher co-medication burden argue for the most conservative exposure.
Baseline biomarkers influencing response: Response depends on how strongly the pathway is already activated, and no clinically available assay measures phosphorylated eIF2α. Response therefore cannot be predicted before dosing.
Pre-existing conditions influencing response: Effects tracked with whether the underlying pathology was driven by this pathway. Conditions not driven by it, such as one amyloid-overexpressing model, showed no response at equivalent exposure.

Discontinuation & Cycling

Not a lifelong intervention: Every published efficacy regimen was short — two or three doses — with effects outlasting the exposure by weeks. Nothing in the literature supports or has tested continuous long-term administration.
Withdrawal effects: None documented, in animals or people. Mechanistically, stopping restores normal pathway signalling rather than producing rebound, but no study has looked for withdrawal after repeated courses.
Tapering: No tapering protocol exists and none is mechanistically indicated, since the compound stabilises an enzyme complex rather than occupying a receptor that could up-regulate during exposure.
Cycling: Untested. The durable effect after brief dosing means the pharmacology fits intermittent use better than daily use, but no study has compared cycled with continuous schedules for efficacy or safety.
Reason to stop early: A rising corrected QT interval, new liver or pancreatic enzyme elevation, a new infection, or any new cancer diagnosis are all grounds to stop immediately given the unresolved risks above.

Sourcing and Quality

Research-chemical status only: ISRIB is sold labelled “for research use only, not for human consumption”. No pharmaceutical-grade, human-tested material exists anywhere, so every available source is by definition unqualified for human use.
Isomer specification is decisive: Only the trans-isomer is active. Product listings that do not explicitly specify trans-ISRIB, or that omit isomeric purity, cannot be assumed to contain the active form.
What to look for: A batch-specific certificate of analysis, purity ≥98% by high-performance liquid chromatography, nuclear magnetic resonance confirmation of structure, and residual-solvent and heavy-metal data. Third-party rather than in-house testing is preferable.
Established laboratory suppliers: Tocris Bioscience, Cayman Chemical, MedChemExpress, APExBIO and Merck (Sigma-Aldrich) supply characterised material with batch documentation. Grey-market vendors selling capsules or solutions provide no comparable documentation.
Formulation is the central obstacle: ISRIB is poorly water-soluble, which is precisely why industry abandoned it. Laboratory work uses dimethyl sulfoxide with polyethylene glycol vehicles that are not suitable for repeated human administration.
Topical routes have been formulated: A cream containing permeation enhancers achieved skin delivery with no detectable systemic exposure, showing the solubility problem is tractable for local use but not for whole-body dosing.

Practical Considerations

Time to effect: In rodents, memory changes appeared within days of a two-to-three-dose course and persisted for at least three weeks. No human time course exists, so this figure cannot be transferred.
Common pitfall — assuming the mouse dose scales: Rodent doses of 0.1–2.5 mg/kg were given by injection into the abdominal cavity. Oral human dosing faces the solubility barrier that ended the compound’s industrial development.
Common pitfall — expecting enhancement of normal cognition: The published effect is restoration of impaired memory in aged or injured brains, not improvement of already-normal function, where results were smaller and less consistent.
Common pitfall — buying the wrong isomer or an untested analogue: Grey-market listings conflate ISRIB with 2BAct and other analogues, one of which was dropped for cardiovascular toxicity in large animals.
Regulatory status: Unapproved in every jurisdiction, with no investigational new drug application for human use. It is not a dietary supplement, so importing it for personal consumption carries customs and legal exposure.
Cost and accessibility: Laboratory-grade material costs roughly £100–300 for 10 mg, which is modest, but no pharmacy dispenses it and no physician can lawfully prescribe it, making supervised access effectively unavailable.
Structural incentive away from ISRIB itself: ISRIB is cheap to synthesise and sold as a research chemical, while its proprietary successors carry drug pricing. Sponsors, and the payers who would reimburse them, have no financial reason to fund trials of the parent compound.
No clinical body endorses it: ALSUntangled, a volunteer academic clinician panel with no commercial stake in its verdicts, found the evidence insufficient and called for pharmacokinetic, safety and efficacy trials before any use.

Interaction with Foundational Habits

Sleep: Indirect and bidirectional. Sleep loss raises phosphorylated eIF2α in the hippocampus, the same signal ISRIB opposes, so poor sleep both increases the pathway activity that ISRIB targets and independently degrades the memory consolidation it is taken to improve. No human timing data exist; rodent dosing occurred during the animals’ rest phase.
Nutrition: Blunting, in both directions. Amino-acid scarcity activates GCN2, one of the four upstream kinases, so extended fasting, protein restriction and ketogenic eating raise pathway activity that ISRIB then opposes — working against the signalling those regimens aim to produce. Practically, poor water solubility means absorption is more plausible with a fat-containing meal than fasted.
Exercise: Potentially blunting. Training transiently activates this stress pathway in muscle, and in aged mice pathway activation rather than inhibition improved muscle stem-cell activation and regeneration, so suppressing it may dampen an adaptive training signal. Practical implication: separate any dosing from training sessions rather than pairing them.
Stress management: Indirect and downstream. Chronic corticosterone exposure activates this pathway, and ISRIB reversed corticosterone-driven ovarian follicle loss and restraint-stress intestinal inflammation in mice. It therefore addresses a consequence of chronic stress rather than the stressor, and does not substitute for reducing the stress load itself.

Monitoring Protocol & Defining Success

Before any exposure, a baseline panel establishes organ function and cardiac conduction against which later values can be read, because no human safety data exist to define expected shifts. The essential baseline set is a complete blood count, a comprehensive metabolic panel covering liver and kidney function, lipase, fasting glucose with insulin, glycated haemoglobin, high-sensitivity C-reactive protein, a 12-lead electrocardiogram, and, for women of reproductive age, anti-Müllerian hormone. A repeatable cognitive battery administered twice at baseline establishes test-retest variability, without which any later change cannot be distinguished from noise. Ongoing monitoring repeats the electrocardiogram and liver and pancreatic enzymes at two weeks and four weeks, then the full panel at three months and every three to six months during continued use, with anti-Müllerian hormone repeated at six months.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	10–26 U/L	Detects liver injury from a compound with unpublished human clearance	ALT is alanine aminotransferase, a liver enzyme. Conventional labs flag only above about 40 U/L. No fasting needed.
AST	10–26 U/L	Confirms and localises any ALT rise	AST is aspartate aminotransferase, released by liver and muscle. Conventional labs flag only above about 40 U/L. Best paired with ALT and creatine kinase.
Lipase	10–60 U/L	Screens for pancreatic irritation, the toxicity that ended PERK-inhibitor development	Draw fasting. Conventional upper limit near 160 U/L sits far above the functional threshold.
Fasting glucose	75–86 mg/dL	Stress-pathway signalling governs glucose handling and transporter expression	Requires an 8–12 hour fast. Conventional range extends to 99 mg/dL. Pair with fasting insulin.
HbA1c	4.9–5.3%	Captures glucose drift that a single fasting value misses	HbA1c is glycated haemoglobin, a roughly three-month average of blood sugar. Conventional range extends to 5.6%. No fasting needed.
hs-CRP	<0.5 mg/L	Tracks the inflammatory tone this pathway both responds to and drives	hs-CRP is high-sensitivity C-reactive protein. The conventional low-risk cut-off is below 1.0 mg/L. Invalid within two weeks of any infection or injury.
eGFR	>90 mL/min/1.73 m²	Kidney clearance matters when elimination routes are unpublished	eGFR is estimated glomerular filtration rate, a measure of kidney filtering. Conventional labs flag only below 60 mL/min/1.73 m². Avoid heavy protein intake and creatine for 48 hours before.
Anti-Müllerian hormone	Above the 50th centile for age; any fall over 12 months is the signal	Detects depletion of the dormant ovarian follicle pool	Anti-Müllerian hormone reflects ovarian reserve. Conventional labs report only whether a value falls inside the broad age-specific reference interval, which spans roughly the 5th to 95th centile. Any cycle day. Women of reproductive age only.
Corrected QT interval	<440 ms in men, <450 ms in women	Screens for the cardiac effect that ended the closest analogue’s development	Measured on a 12-lead electrocardiogram. Conventional labs flag only above 450 ms in men and 470 ms in women. Correct for heart rate. Repeat at the same time of day.
Cognitive battery score	No established target; track change against the individual’s own two baseline sessions	Measures the claimed benefit rather than a proxy for it	Use the same validated battery, same time of day, caffeine held constant. Practice effects inflate early gains.

Qualitative markers are as informative as the panel here, because the claimed benefit is subjective before it is measurable:

Ease of recalling names, appointments and where objects were placed
Speed of picking up genuinely new material rather than rehearsing familiar material
Mental clarity in the late afternoon, when age-related decline is most noticeable
Sleep quality and dream recall, since the pathway is engaged by sleep loss
Absence of new palpitations (an uncomfortable awareness of the heartbeat), unexplained fatigue, upper abdominal pain, or reduced exercise tolerance

Emerging Research

Fosigotifator in vanishing white matter disease: NCT05757141 is an open-label Phase 1b/2 study in 50 adults, children and infants with this disorder (an inherited brain-insulation disease), run by Calico Life Sciences. Primary endpoints are adverse events, vital signs, electrocardiogram change and drug exposure. Recruiting, with primary completion estimated for November 2027.
Fosigotifator in motor neuron disease — a negative result: NCT05740813, the 310-participant Regimen F of a Phase 2/3 platform trial, missed its primary disease-progression endpoint at both doses. The compound was safe and well tolerated, with an exploratory high-dose muscle-strength signal that remains unconfirmed.
A second eIF2B activator, same outcome: NCT05842941, the 249-participant Regimen G of the same platform trial, tested Denali’s DNL343 and also completed without meeting its progression endpoint. Two independent compounds of this class failing the same disease weakens the case for the mechanism there.
Depression programme halted: NCT06618118, a 20-participant Phase 1 adverse-event study of fosigotifator in major depressive disorder, was terminated by company decision in September 2025. An earlier motor neuron disease Phase 1 study, NCT04948645, was also terminated for the same reason.
The direction of modulation is genuinely open: Brown et al., 2025 found that activating this pathway, not inhibiting it, improved aged muscle stem-cell activation and muscle regeneration in mice. If replicated, the same lever may need opposite settings in brain and muscle.
Whether inhibition is safe long-term is unresolved: Xu et al., 2024 showed impaired proteasomal clearance in treated cells, while Chen et al., 2025 doubled lifespan in a brain-insulation disease model. Chronic-toxicity work would decide between these, and none is published.
Genotype-specific responsiveness is being mapped: Scagliola et al., 2025 used prime editing to link specific eIF2B mutations to a split stress response and white-matter degeneration, work that could identify who responds to this class and who does not.

Conclusion

ISRIB is a laboratory compound that releases a cellular brake on protein production. In rodents this reversed memory loss from ageing and head injury, protected the cells that insulate nerve fibres, restored brain sugar uptake in dementia models, and awakened dormant egg cells. Those findings are consistent, and every one comes from animals or cultured cells. No person has taken ISRIB in a registered trial.

That gap defines the risk picture too. The concerns — impaired clearing of damaged proteins, worsened outcomes in a motor-nerve disease model, unpredictable effects on tumours and infections, silent loss of a woman’s egg reserve, and heart effects seen with a close chemical relative — are all reasoned from mechanism or animals. None has been ruled in or out in people.

The compound’s development was taken over by parties with a direct commercial stake in this drug class, chiefly Calico Life Sciences and AbbVie, whose own successor compound failed its main goal in a fatal nerve disease. The one clinician group to review real-world use — a volunteer panel with no commercial stake in the answer — declined to endorse it. Neither the enthusiastic nor the sceptical position rests on human outcome data, because none exists.

For someone tracking longevity compounds, ISRIB sits at the far speculative end: a well-understood mechanism, a striking animal record, a compound its own developers abandoned because it dissolves too poorly, and an entirely blank human safety file.

Top - Benefits - Risks - Protocol

ISRIB for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Memory and Learning Performance ⚠️ Conflicted

Neuronal and Myelin Preservation

Locomotor Recovery After Spinal Cord Injury

Cerebral Glucose Uptake

Hearing Preservation During Platinum Chemotherapy

Ovarian Follicle Activation

Reduced Cellular Senescence in Injured Lung

Depression-Like Behaviour Under Chronic Stress

Protection of the Intestinal Barrier Under Chronic Stress

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Speculative 🟨

Impaired Clearance of Damaged Proteins

Accelerated Motor Neuron Loss

Altered Response to Infection ⚠️ Conflicted

Altered Tumour Behaviour ⚠️ Conflicted

Accelerated Depletion of Ovarian Reserve

Cardiovascular Effects Seen with Close Analogues

Harm from Long-Term Suppression of a Protective Pathway

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion